NasdaqCM - Nasdaq Real Time Price USD

Crescent Biopharma, Inc. (CBIO)

13.48 -0.59 (-4.19%)

At close: October 30 at 4:00:02 PM EDT

13.48 0.00 (0.00%)

After hours: October 30 at 4:00:08 PM EDT

Trade CBIO on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for CBIO

Previous Close 14.07
Open 13.94
Bid 10.16 x 200
Ask 17.17 x 200
Day's Range 13.31 - 14.56
52 Week Range 8.72 - 27.41
Volume 146,585
Avg. Volume 347,376
Market Cap (intraday) 500.739M
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -7.63
Earnings Date --
Forward Dividend & Yield -- (0.00%)
1y Target Est 31.50
Zacks Rating Neutral

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

crescentbiopharma.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CBIO

13.66%

S&P 500 (^GSPC)

10.73%

1-Year Return

CBIO

7.75%

S&P 500 (^GSPC)

11.11%

3-Year Return

CBIO

89.63%

S&P 500 (^GSPC)

81.91%

5-Year Return

CBIO

106.42%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -24.84M

Profit Margin 0.00%

FY25

FY26

-80M

-60M

-40M

-20M

0.0%

Analyst Price Targets

27.00

31.50 Average

13.48 Current

36.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/19/2026

Analyst HC Wainwright & Co.

Rating Action Reiterates

Rating Buy

Price Action Maintains

Price Target 36 -> 36

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

11.88M
Net Income Avi to Common (ttm)

-165.12M
Diluted EPS (ttm)

-7.63

Balance Sheet and Cash Flow

Total Cash (mrq)

171.59M
Total Debt/Equity (mrq)

0.88%
Levered Free Cash Flow (ttm)

--

BNTC

AKTX

PULM

CLRB

CALA

U.S. markets closed

Crescent Biopharma, Inc. (CBIO)

Trading disclosure

5.15%

-7.61%

-39.74%

13.66%

7.75%

-92.94%

-98.70%

Crescent Biopharma, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch